Status:
UNKNOWN
LAIV (Flumist®) Administration in CF Patients
Lead Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborating Sponsors:
Ministere de la Sante et des Services Sociaux
Canadian Cystic Fibrosis Foundation
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
2-18 years
Brief Summary
Influenza (the "flu") is one of the most common respiratory viruses associated with respiratory deteriorations in children and adolescents with cystic fibrosis. These deteriorations usually mean antib...
Detailed Description
The literature demonstrates a significant impact of influenza on the disease course of children with cystic fibrosis (CF) and superior efficacy of live-attenuated influenza vaccine (LAIV - Flumist®) c...
Eligibility Criteria
Inclusion
- followed in one of the participating clinics
- considered in stable condition prior to enrollment as per their physician,
Exclusion
- allergic to eggs or other vaccine components
- patients for whom LAIV is contraindicated (i.e. on oral steroids for an acute asthma exacerbation or with a medically-attended wheezing episode in the 7 days prior to immunization)
- participants with clinically significant nasal polyps
- have a significant febrile illness (oral temperature ≥ 380C) at day of vaccination
- pregnant women
- immunosuppressed subjects
Key Trial Info
Start Date :
August 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2015
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT01885169
Start Date
August 1 2013
End Date
December 1 2015
Last Update
September 16 2014
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Vaccine Evaluation Centre
Vancouver, British Columbia, Canada, V5Z 4H4
2
The Montreal Children's Hospital
Montreal, Quebec, Canada, H3H 1P3
3
Centre Hospitalier de l'Université Laval
Québec, Quebec, Canada, G1V 4G2